(October 21, 2018) New Jersey Governor Phil Murphy and his senior state team participated at a round table that took place at Chamber member Teva. Governor Murphy and the First Lady met with a dozen Israeli companies from the biotech and pharma industry.

The Round Table was organized jointly with Teva and the U.S. Commercial Section's SelectUSA team. After signing an MOU with Teva CEO, Kåre Schultz, regarding the consolidation of Teva operations in the U.S. into New Jersey, the Governor presented his vision of recreating New Jersey as an innovation state.

The Governor, who only took office earlier this year, acknowledge that although New Jersey lost its once held leadership in the Bio-Pharma industry to states such as Massachusetts and California, NJ still has major relevant assets and some of the biggest pharma companies still do call NJ home. The companies including both biotech startups and big Pharma such as Teva and Abbvie, had a great opportunity to interact with the Governor and his senior team and explore mutually beneficial opportunities to establishing presence in New jersey, that enjoys among others the largest number of direct daily flights from Tel Aviv.